Effect of coenzyme Q10 supplement to decrease cardiac complications predictor factors in β-Thalassemia major patients

Determining the effect of coenzyme Q10 supplementation in reducing the level of cardiac complications predicting factors in patients with beta Thalassemia major referred to Hajar Hospital.

The present semi-experimental study will be conducted on 50 thalassemia major patients. This study is a phase 3 clinical trial. This study is before and after and does not have a control group. In addition to the standard treatment (iron chelators such as deferoxamine, deferasirox, etc), the patients also receive a 100 mg co-enzyme Q10 tablet daily for eight weeks.

Fifty patients are chosen among the thalassemia patients referred to Shahrekord Hajar Hospital in 2023. These participants are chosen based on similarities (individuals with similar blood collection intervals). A before-and-after investigation will be carried out. There is no control group. Before intervention the following parameters proBNP, D-dimer, Troponin, EF, PAP, TRG, TAPSE, IVSD, LVDS, PW, AVPG, RVD, RVSM, LVDD, AO, LA, E, E' ,E wave ECG will be checked, and then, along with the standard treatment, they will be given a 100 mg co-enzyme Q10 tablet daily for eight weeks and the mentioned parameters are checked again.

Entry criteria: people with thalassemia major, non-entry criteria: occurrence of infection and inflammation and death of the patient, pregnancy or breastfeeding.

The study will be a single group comparison before and after. The intervention group receives standard treatment + 100 mg Q10 tablets

Blood troponin level Blood ProBNP blood D-dimer level Echocardiography examination in terms of EF PAP TRG TAPSE IVSD LVDS PW AVPG RVD RVSM LVDD AO LA E E' E wave Electrocardiography examination in terms of Rhythm rate axis P wave PR interval QRS wave ST segment T wave QT interval

To share the data and documents of this research, only the information related to the main outcome will be shared. Also, files that can be published and do not violate people's privacy will be published.

The access period will start 6 months after the results are published.

Our data will only be available to researchers working in academic and scientific institutions.

If there are conditions, all our data will be shared except personal information of people. The use of our data will only be allowed for similar research and review of our data by other researchers. All those who work in universities and scientific centers and decide to conduct similar research or check the accuracy of our data can access our data.

In order to receive information, all eligible people can collect data by referring to the person in charge of the project. The contact methods are the email address nimanimanimana@gmail.com or the contact number 00989140868595.

To receive information after sending the request, the requests will be reviewed within 10 days. If the above conditions are met, the information will be sent to the provided email within 30 days at most.